Use of antibiotic by children with cystic fibrosis does not result in improved lung function

May 04, 2010

Children and adolescents with cystic fibrosis who received the antibiotic azithromycin did not experience improved lung function, compared to patients who received placebo, according to a study in the May 5 issue of JAMA.

"A vicious cycle of infection and inflammation causes progressive lung destruction and in patients with (CF). Treatment strategies have therefore included both antimicrobial and anti-inflammatory agents," the authors write. There has been increasing evidence over the past decade that azithromycin, an antibiotic with both antimicrobial and anti-inflammatory activity, benefits individuals with CF. "Azithromycin is recommended as therapy for CF patients with chronic Pseudomonas aeruginosa [a bacteria] infection, but there has not been sufficient evidence to support the benefit of azithromycin in other patients with CF."

Lisa Saiman, M.D., M.P.H., of Columbia University, New York, and colleagues conducted a ran¬domized, placebo-controlled trial involving children and ado¬lescents with CF who were uninfected with P aeruginosa to determine if azithromycin would improve or reduce pulmonary exacerbations. The trial was conducted from February 2007 to July 2009 at 40 CF care centers in the United States and Canada. Of the 324 participants screened, 260 met study criteria, were randomized and received either the study drug (n = 131) or placebo (n = 129). The average age of the participants was 10.7 years.

The researchers found that treatment with azithromycin for 24 weeks, compared with placebo, did not result in improved , as measured by the change in FEV1 (the volume of air that can be forced out in one second after taking a deep breath). "However, analyses of exploratory end points demonstrated that when compared with the placebo group, the azithromycin group had a 50 percent reduction in pulmonary exacer¬bations, 27 percent reduction in the initia¬tion of new oral antibiotics (other than azithromycin), 1.3 lbs. weight gain, and 0.34-unit increase in body mass index. There were no differences in treatment groups in the use of intravenous or inhaled antibiot¬ics or hospitalizations," the authors write.

Participants in the azithromycin group had less cough and less productive cough, compared with placebo participants.

"Further studies of are warranted to further investigate its potential use in this population," the researchers conclude.

Explore further: UN implores all countries to help on Ebola

More information: JAMA. 2010;303[17]:1707-1715.

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Obama addresses West Africans on facts about Ebola

7 hours ago

President Barack Obama urged West Africans on Tuesday to wear gloves and masks when caring for Ebola patients or burying anyone who died of the disease. He also discouraged the traditional burial practice ...

Gluten-free diet benefits asymptomatic EmA+ adults

7 hours ago

(HealthDay)—Asymptomatic individuals with endomysial antibodies (EmA) benefit from a gluten-free diet (GFD), according to a study published in the September issue of Gastroenterology.

Another US health worker infected with Ebola

8 hours ago

A third American health worker has tested positive for the Ebola virus while working with patients in West Africa, the Christian missionary group SIM said Tuesday.

UN implores all countries to help on Ebola

10 hours ago

The international group Doctor Without Borders warned Tuesday that the world is 'losing the battle' against Ebola, while U.N. officials implored all countries to quickly step up their response by contributing health experts ...

Travel restrictions could worsen Ebola crisis: experts

14 hours ago

Travel restrictions could worsen West Africa's Ebola epidemic, limiting medical and food supplies and keeping out much-needed doctors, virologists said Tuesday as the disease continued its deadly spread.

User comments : 0